Table 1.
Summary Characteristics of 14 HIV-Infected Pregnant Women Who Used Raltegravir Late in Pregnancy for HIV-1 Prevention of Mother-to-Child Transmission in Bahia, Brazil
| Case | Gestational age at RGV initiation (weeks) | VL at RGV initiation (copies/ml) | ARV drugs during current pregnancy | Gestational age at delivery (weeks) | Exposure to RGV (days) | VL at delivery (copies/ml) | Decline of VL (log) from RGV initiation to delivery |
|---|---|---|---|---|---|---|---|
| 1 | 35 | 61.505 | ZDV+3TC+LPV/r+RGV | 37 | 7 | Unknown | — |
| 2 | 36 | 27.026 | ZDV+3TC+TDF+DRV/r+RGV | 38 | 20 | <50 | 2.74 |
| 3 | 37 | 114.059 | ZDV+3TC+RGV | 40 | 18 | <50 | 3.36 |
| 4 | 35 | 68.891 | ZDV+3TC+DRV/r+RGV | 38 | 22 | <50 | 3.14 |
| 5 | 38 | 959 | ZDV+3TC+LPV/r+RGV | 39 | 7 | 139 | 0.84 |
| 6 | 35 | 129.842 | ZDV+3TC+LPV/r+RGV | 37 | 9 | Unknown | — |
| 7 | 36 | 391.535 | ZDV+3TC+LPV/r+RGV | 39 | 32 | <50 | 3.90 |
| 8 | 37 | 7.361 | ZDV+3TC+RGV | 39 | 15 | 64 | 3.06 |
| 9 | 35 | 15.957 | ZDV+3TC+LPV/r+RGV | 38 | 18 | <50 | 2.51 |
| 10 | 36 | 95.734 | ZDV+3TC+ATV/r+RGV | 39 | 17 | 457 | 2.33 |
| 11 | 36 | 43.703 | ZDV+3TC+RGV | 38 | 17 | 194 | 2.36 |
| 12 | 34 | 5.408 | ZDV+3TC+RGV | 37 | 7 | <50 | 2.04 |
| 13 | 37 | 6.168 | ZDV+3TC+LPV/r+RGV | 39 | 14 | Unknown | — |
| 14 | 35 | 4.665 | ZDV+3TC+RGV | 38 | 25 | <50 | 1.97 |
RGV, raltegravir; VL, viral load; ARV, antiretroviral; ZDV, zidovudine; 3TC, lamivudine; TDF, tenofovir; LPV/r, lopinavir/r; ATV/r, atazanavir/r; DRV/r, darunavir/r.